1. Home
  2. TRVI vs BDJ Comparison

TRVI vs BDJ Comparison

Compare TRVI & BDJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$13.60

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Blackrock Enhanced Equity Dividend Trust

BDJ

Blackrock Enhanced Equity Dividend Trust

HOLD

Current Price

$9.20

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVI
BDJ
Founded
2011
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
TRVI
BDJ
Price
$13.60
$9.20
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
$21.55
N/A
AVG Volume (30 Days)
982.4K
491.6K
Earning Date
05-05-2026
01-01-0001
Dividend Yield
N/A
8.85%
EPS Growth
31.91
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.41
$8.42
52 Week High
$16.12
$9.76

Technical Indicators

Market Signals
Indicator
TRVI
BDJ
Relative Strength Index (RSI) 45.75 52.95
Support Level $13.12 $8.91
Resistance Level $14.57 $9.25
Average True Range (ATR) 0.53 0.10
MACD -0.11 -0.00
Stochastic Oscillator 23.23 63.47

Price Performance

Historical Comparison
TRVI
BDJ

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

About BDJ Blackrock Enhanced Equity Dividend Trust

BlackRock Enhanced Equity Dividend Trust is a closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option to enhance distributions to its shareholders.

Share on Social Networks: